Results for tag: "Belviq"

Belviq is an anti-obesity drug developed by Arena Pharmaceuticals and approved by the U.S. Food and Drug Administration in 2012. It is a serotonin 2C receptor agonist, which works by activating the serotonin receptors in the brain to reduce appetite and food cravings. Belviq is prescribed to overweight or obese adults in combination with a reduced-calorie diet and exercise program. It is intended to be used as a long-term treatment for weight management. Belviq is available in the United States, Canada, and Mexico. It is marketed by Eisai Inc. in the United States and by Eisai Inc. and Arena Pharmaceuticals in Canada and Mexico. Other companies involved in the Belviq market include Vivus, Inc., Orexigen Therapeutics, Inc., and Novo Nordisk A/S. Show Less Read more